Cardiac Troponin Diagnostics—Forecasts and Opportunities to 2025
Cardiac Troponin Diagnostics—Forecasts and Opportunities to 2025
Demand for High Sensitivity Point-of-Care Testing Enhance Growth Potential
16-Nov-2022
North America
$4,950.00
Special Price $4,455.00 save 10 %
Description
Cardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare professionals to use cTn diagnostics. In addition, a rising number of patients visit emergency departments (EDs) with cardiac complaints, increasing ED demand for kits
that can rapidly rule MI in or out. Both factors serve as significant drivers of the cTn diagnostics market.
Hospitals and clinical laboratories adopt high-sensitivity (hs) assays because of their ability to detect troponin in lower concentrations. The point-of-care testing (POCT) of cTn grows rapidly due to its rising applications in EDs and remote locations. POCT can provide rapid results in a shorter period than lab-based tests. In addition, companies such as QuidelOrtho and Siemens Healthineers have developed high-sensitivity POCT cTn assays that provide accurate results within a few minutes.
In this report, Frost & Sullivan overviews the cTn diagnostics market and includes troponin I and troponin T. Our testing locations are independent laboratories, physicians’ offices, urgent care and nursing facilities, inpatient hospitals, and emergency rooms. The study covers sensitive and
hs-cTn tests.
The report also includes the following:
• Market size by revenue, covering historic and forecast data by segment (lab-based tests and POCT) and region (North America, Europe,
Asia-Pacific, and the rest of the world)
• Challenges and drivers
• Competitive landscape, including company market share for lab-based tests and POCT
• Future trends and growth opportunities for stakeholders
North America is the leading region in the cTn diagnostics market, with hospitals and laboratories shifting toward high-sensitivity assays following approval from the United States Food and Drug Administration in 2017. Frost & Sullivan’s research shows high consolidation in the cTn diagnostics market, with players such as Abbot, Roche, and Siemens Healthineers dominating. New players are entering this market, especially in the POCT segment.
Table of Contents
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Cardiac Troponin (cTn) Diagnostics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Cardiac Biomarkers
Timeline for Cardiac Biomarkers for MI
cTns
Clinical Pathway for MI Diagnosis
cTn Diagnostics
cTn Diagnostics (continued)
Scope of Analysis
Segmentation
Competitors
Growth Metrics
Growth Drivers
Growth Restraints
Forecast Assumptions
Revenue Forecast
Revenue Forecast by Product Type
Revenue Forecast by Region
Revenue Forecast Analysis
Revenue Forecast Analysis (continued)
Revenue Forecast Analysis by Region
Competitive Environment
Revenue Share
Revenue Share Analysis
Company Mapping
Companies to Watch
High-sensitivity Troponin Diagnostic—Emerging Applications
New Biomarkers for MI
Growth Metrics
Revenue Forecast
Revenue Forecast by Region
Forecast Analysis
Growth Metrics
Revenue Forecast by Product Type
Revenue Forecast by Region
Forecast Analysis
Growth Opportunity 1: Rapid Diagnostics for EDs
Growth Opportunity 1: Rapid Diagnostics for EDs (continued)
Growth Opportunity 2: hs-cTn POCT
Growth Opportunity 2: hs-cTn POCT (continued)
Growth Opportunity 3: Digital Health and Diagnostics Inter-convergence Model
Growth Opportunity 3: Digital Health and Diagnostics Inter-convergence Model (continued)
Growth Opportunity 4: Specific and Sensitive Assays for Rapid MI Detection
Growth Opportunity 4: Specific and Sensitive Assays for Rapid MI Detection (continued)
Your Next Steps
Why Frost, Why Now?
List of Exhibits
Legal Disclaimer
Popular Topics
Industries | Healthcare |
---|---|
No Index | No |
Is Prebook | No |
Podcast | No |
WIP Number | PDB7-01-00-00-00 |